Loading
NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.19, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Squamous Cell Carcinoma.
In plain words · NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2.
No product in this corpus aims at NSD3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2000. Earliest sequence paper UniProt cites for the protein: Xu et al, 2000, "A novel gene from human dendritic cells". Source.
Sources: HGNC HGNC:12767 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BZ95 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000147548 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: colorectal cancer 0.51, skin cancer 0.52, breast cancer 0.54 (GraphQL API, CC0)); IntOGen NSD3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression. Location: Nucleus; Chromosome (UniProt). Locus 8p11.23 (HGNC).
Query for this target: (TITLE:"NSD3" OR ABSTRACT:"NSD3" OR TITLE:"nuclear receptor binding SET domain protein 3" OR ABSTRACT:"nuclear receptor binding SET domain protein 3" OR TITLE:"Histone-lysine N-methyltransferase NSD3" OR ABSTRACT:"Histone-lysine N-methyltransferase NSD3" OR TITLE:"FLJ20353" OR ABSTRACT:"FLJ20353" OR TITLE:"WHISTLE" OR ABSTRACT:"WHISTLE" OR TITLE:"KMT3F" OR ABSTRACT:"KMT3F") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NSD3, not a curated reading list.